10-Q: Vivani Medical Q1 2026 Update: Focus on Biopharm, Cortigent Spin-off

Vivani Medical reports Q1 2026 results, detailing progress in its Biopharm Division, continued operational expenses, and strategic considerations for its Cortigent subsidiary.

Summary

• Vivani Medical, Inc. filed its Form 10-Q for the quarterly period ended March 31, 2026.
• The company reported a net loss of $6.8 million for the quarter, compared to $6.3 million in the same period of 2025.
• Operating expenses increased slightly to $6.8 million from $6.6 million year-over-year.
• Research and development expenses were $4.4 million, up from $4.2 million in Q1 2025, primarily due to increased clinical trial and development expenses in the Biopharm Division.
• General and administrative expenses were $2.4 million, up from $2.3 million, attributed to increased professional services.
• The company's cash and cash equivalents increased to $19.7 million from $16.2 million at the end of 2025.
• Vivani is exploring strategic options for its Cortigent subsidiary, including a potential spin-off or IPO, aiming to separate its neurostimulation technology.
• The company estimates its current cash will fund operations through the second quarter of 2027, but additional capital will be required for continued operations beyond that point.
• The company continues to focus on its NanoPortal technology for ultra long-acting subdermal drug implants, with lead programs NPM-139 and NPM-133 in development for chronic weight management and type-2 diabetes, respectively.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the increased net loss, ongoing operational expenses without revenue, and the critical need for future financing, despite progress in R&D and strategic reviews.

Positives

• Increase in cash and cash equivalents to $19.7 million from $16.2 million, providing a longer runway.
• Continued progress in the Biopharm Division, with increased R&D spending indicating ongoing development efforts.
• Exploration of strategic options for Cortigent, which could unlock value for shareholders and allow focused development of the Biopharm division.
• Estimated cash runway extending to mid-2027, providing a buffer for ongoing operations.

Negatives

• Net loss of $6.8 million for the quarter, an increase from $6.3 million in the prior year's quarter.
• Continued operating losses and negative cash flows are expected for the foreseeable future.
• Substantial additional financing is required to pursue business objectives, with no assurance of availability on acceptable terms.
• The company has no products approved for commercial sale and a limited operating history.
• The legal proceedings related to the MOU termination with Pixium Vision SA and the Oppenheimer & Co. Inc. complaint represent ongoing financial and operational risks.

Risks

• The company is a clinical-stage company with no approved products, dependent on the success of its product candidates.
• Substantial additional financing is required, and failure to obtain it could force delays or termination of development efforts.
• Clinical development is lengthy, expensive, and uncertain, with no guarantee of favorable results or regulatory approval.
• Manufacturing challenges and reliance on third parties could increase costs and limit supply.
• Intellectual property risks, including potential infringement and challenges to patent validity.
• The company faces significant competition in the biopharmaceutical industry.
• The spin-off of Cortigent may not be completed as anticipated or may not yield expected benefits.
• Ongoing legal proceedings with Pixium Vision SA and Oppenheimer & Co. Inc. could result in significant financial burdens and diversion of management resources.
• The company's ability to continue as a going concern beyond mid-2027 is dependent on raising additional capital.

Future Outlook

The company expects to continue incurring operating losses and negative operating cash flows for the foreseeable future. Its ability to continue as a going concern beyond mid-2027 is dependent on raising additional capital. The company estimates its current cash will fund operations through the second quarter of 2027. Strategic options for Cortigent are being explored, with a potential spin-off or IPO being considered.

Management Comments

• The company's main priority is the further development of its miniature, ultra long-acting drug implant candidate programs.
• Management remains committed to identifying and exploring strategic options for its pioneering neurostimulation systems from legacy company Second Sight.
• The company estimates that currently available cash will provide sufficient funds to enable the Company to meet its planned obligations through the second quarter of 2027.
• If the company is unable to complete Cortigent's transition to becoming a separate reporting company and secure additional funding, it would need to discontinue Cortigent's operations to preserve projected liquidity.

Industry Context

StockSavvy.ai notes that Vivani Medical operates in the highly competitive and capital-intensive biopharmaceutical sector, focusing on chronic disease treatments through novel drug delivery systems. The company's strategy of developing long-acting implants addresses a significant unmet need related to medication adherence, a common challenge in chronic disease management. The ongoing exploration of strategic options for its neurostimulation division (Cortigent) suggests a potential shift in focus towards its core biopharmaceutical assets.

Comparison to Industry Standards

• The company's net loss of $6.8 million for the quarter is consistent with early-stage biopharmaceutical companies that are pre-revenue and investing heavily in research and development.
• The cash burn rate of approximately $6.2 million for operating activities in Q1 2026 is within the typical range for companies at this stage, but highlights the critical need for continued fundraising.
• The focus on GLP-1 implants for weight management and type-2 diabetes places Vivani in a competitive space with major pharmaceutical players like Novo Nordisk, AstraZeneca, and Eli Lilly, who also have significant investments in this therapeutic area.
• The company's reliance on equity financings (registered direct offerings and private placements) is a standard practice for biopharmaceutical companies needing to fund extensive clinical trials and development.

Legal Proceedings

• An opposition filed by Pixium Vision SA in the European Patent Office challenging a Cortigent patent was resolved by abandonment of the patent in February 2025.
• A lawsuit filed by Pixium Vision SA in the Paris Commercial Court related to the termination of a Memorandum of Understanding (MOU) is ongoing, with an appeal pending before the Paris Court of Appeal.
• Oppenheimer & Co. Inc. filed a complaint for breach of contract and other claims related to a placement agent agreement, with discovery commencing on the remaining claim after a motion to dismiss was partially granted.

Related Party Transactions

• Issuance of common stock to a related party entity affiliated with an independent director in connection with 2025 Private Sales Transactions.
• Issuance of common stock to a related party entity affiliated with an independent director in connection with the 2026 Private Placement.

Stakeholder Impact

• Shareholders: Potential dilution from future equity offerings, continued uncertainty regarding profitability, but potential upside from successful product development and strategic separation of Cortigent.
• Employees: Continued focus on R&D and potential growth, but also risk associated with the company's financial stability and need for future capital.
• Creditors: No significant debt mentioned, primary financial risk is to equity holders.
• Suppliers: Continued demand for R&D and manufacturing services, subject to the company's ability to secure funding.

Next Steps

• Continue development of miniature, ultra long-acting subdermal drug implant candidates (NPM-139, NPM-133, NPM-115, OKV-119).
• Initiate Phase 1 clinical trials for NPM-139 and NPM-133 in mid-2026.
• Continue exploring strategic options for Cortigent, Inc., including a potential IPO or spin-off.
• Secure additional financing to support operations beyond mid-2027.
• Complete remaining tranche closings under 2025 Private Sales Transactions in 2026.

Key Dates

Recommendation

Vivani Medical remains a speculative, clinical-stage biopharmaceutical company with significant risks related to financing and product development success. While the company is making progress in its core Biopharm division and exploring strategic options for its Cortigent subsidiary, the increased net loss and continued reliance on external capital necessitate a cautious approach. Investors should monitor future financing rounds, clinical trial progress, and the outcome of strategic initiatives for Cortigent. Given the inherent risks and lack of near-term revenue, a 'hold' recommendation is appropriate for existing investors, while new investment should be considered highly speculative.

Keywords

Vivani Medical, Form 10-Q, Quarterly Report, Biopharmaceutical, Clinical Stage, Drug Implant, NanoPortal Technology, NPM-139, NPM-133, Weight Management, Type 2 Diabetes, Cortigent, Spin-off, Financing, Net Loss, Operating Expenses, SEC Filing